title: Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment.
abstract: OBJECTIVE
  The aim of the present study was to assess the prognostic value of changes in left ventricular hypertrophy in hypertensive patients with time.
  
  
  METHODS
  Two hundred and fifteen uncomplicated hypertensive patients underwent a high-quality baseline echocardiogram for left ventricular anatomy evaluation and in 151 of those patients the echocardiographic examination was repeated 10 +/- 1.4 years after the initial study.
  
  
  METHODS
  Left ventricular mass index changes were evaluated, in relation to the incidence of non-fatal cardiovascular events, adjusted for traditional cardiovascular risk factors.
  
  
  RESULTS
  According to the presence or absence of left ventricular hypertrophy (left ventricular mass index > 134 g/m2 in men and > 110 g/m2 in women) at baseline and at the end of follow-up study, patients were divided into four groups: with normal left ventricular mass at both examinations (n = 78), with regression of left ventricular hypertrophy (n = 32), with persistence of left ventricular hypertrophy (n = 34) and with hypertrophy development (n = 7). After adjustment for traditional cardiovascular risk factors, the cumulative incidence of non-fatal cardiovascular events was significantly higher in the group of patients without regression of left ventricular hypertrophy. Cox survival analysis showed the presence of left ventricular hypertrophy at the end of follow-up study to be the most important factor related to cardiovascular events.
  
  
  CONCLUSIONS
  The present findings strongly indicate that the lack of decrease or the increase of left ventricular mass after antihypertensive treatment can be associated with a higher risk for cardiovascular events, which is significantly reduced and almost normalized by complete regression of left ventricular hypertrophy.
authors.affiliation: Cattedra di Semeiotica e Metodologia Medica, UOP Scienze Mediche, Università di Brescia, Italy.
authors.forename: M L
authors.initials: ML
authors.lastname: Muiesan
authors.forename: M
authors.initials: M
authors.lastname: Salvetti
authors.forename: D
authors.initials: D
authors.lastname: Rizzoni
authors.forename: M
authors.initials: M
authors.lastname: Castellano
authors.forename: F
authors.initials: F
authors.lastname: Donato
authors.forename: E
authors.initials: E
authors.lastname: Agabiti-Rosei
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004452:Echocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D017379:Hypertrophy, Left Ventricular / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors
chemical_list: D000959:Antihypertensive Agents